A single recurrent mutation in the regulatory subdomain of a bone morphogenetic protein type I receptor kinase has been linked to heterotopic ossification in classic fibrodysplasia ossificans progressiva (FOP). As a result of a substitution at 1 residue by only 1 other side chain (Arg206His) in just 1 of the 4 type I BMP receptors (ALK2/ACVR1), soft connective tissues progressively metamorphose through an endochondral process into cartilage that is replaced by bone. The substitution of arginine for histidine, also a basic residue yet with the singular property of ionization/protonation over the physiological pH range, led to the hypothesis of an aberrant, pH-sensitive switch mechanism for the ligand-independent activation of BMP signaling through the mutant receptor kinase in patients presenting with classic FOP. To test a potential aspect of the putative pH-dependent mechanism, i.e. loss of autoinhibition of the kinase mediated by the inhibitory protein FKBP12, in vitrointeraction analyses with purified wild-type and R206H ALK2 kinase and FKBP12 proteins were performed. Interactions between the kinases and inhibitory proteins were analyzed qualitatively and quantitatively by native gel electrophoresis and HPLC size exclusion chromatography and with an optical biosensor (Octet; ForteBio). Binding of inhibitory protein by the R206H mutant was diminished 3-fold relative to the wild type kinase at a physiological pH, yet below this value (<∼7.5) pronounced nonspecific interactions, particularly with the mutant, prevented comparative evaluations. In conclusion, substitution with histidine leads to partial loss of inhibition of the mutant type I receptor through diminished binding of FKBP12, which may act as a gradient reader in morphogenetic contexts.

Keywords:
BMP/TGF-β signaling, FKBP12, Ser/Thr kinase receptors, Skeletal dysplasias, Fibrodysplasia ossificans progressiva
1.
Ahn, J., L. Serrano de la Pena, E.M. Shore, F.S. Kaplan (2003) Paresis of a bone morphogenetic protein-antagonist response in a genetic disorder of heterotopic skeletogenesis. J Bone Joint Surg Am 85: 667–674.
2.
de la Pena, L.S., P.C. Billings, J.L. Fiori, J. Ahn, F.S. Kaplan, E.M. Shore (2005) Fibrodysplasia ossificans progressiva (FOP), a disorder of ectopic osteogenesis, misregulates cell surface expression and trafficking of BMPRIA. J Bone Miner Res 20: 1168–1176.
3.
Fiori, J.L., P.C. Billings, L.S. de la Pena, F.S. Kaplan, E.M. Shore (2006) Dysregulation of the BMP-p38 MAPK signaling pathway in cells from patients with fibrodysplasia ossificans progressiva (FOP). J Bone Miner Res 21: 902–909.
4.
Greenwald, J., J. Groppe, P. Gray, E. Wiater, W. Kwiatkowski, W. Vale, S. Choe (2003) The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly. Mol Cell 11: 605–617.
5.
Groppe, J., J. Greenwald, E. Wiater, J. Rodriguez-Leon, A.N. Economides, W. Kwiatkowski, M. Affolter, W.W. Vale, J.C. Belmonte, S. Choe (2002) Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature 420: 636–642.
6.
Groppe, J., C.S. Hinck, P. Samavarchi-Tehrani, C. Zubieta, J.P. Schuermann, A.B. Taylor, P.M. Schwarz, J.L. Wrana, A.P. Hinck (2008). Cooperative assembly of TGF-β superfamily signaling complexes is mediated by two disparate mechanisms and distinct modes of receptor binding. Mol Cell 29: 157–168.
7.
Groppe, J.C., E.M. Shore, F.S. Kaplan (2007) Functional modeling of the ACVR1 (R206H) mutation in FOP. Clin Orthop Relat Res 462: 87–92.
8.
Huse, M., Y.G. Chen, J. Massagué, J. Kuriyan (1999) Crystal structure of the cytoplasmic domain of the type I TGFβ receptor in complex with FKBP12. Cell 96: 425–436.
9.
Huse, M., J. Kuriyan (2002) The conformational plasticity of protein kinases. Cell 109: 275–282.
10.
Huse, M., T.W. Muir, L. Xu, Y.G. Chen, J. Kuriyan, J. Massagué (2001) The TGFβ receptor activation process: an inhibitor-to substrate-binding switch. Mol Cell 8: 671–682.
11.
Kaplan, F.S., M. Xu, P. Seemann, J.M. Connor, D.L. Glaser, L. Carroll, P. Delai, E. Fastnacht-Urban, S.J. Forman, G. Gillessen-Kaesbach, J. Hoover-Fong, B. Köster, R.M. Pauli, W. Reardon, S.-A. Zaidi, M. Zasloff, R. Morhart, S. Mundlos, J. Groppe, E.M. Shore (2009) Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat 30: 379–390.
12.
Shafritz, A.B., E.M. Shore, F.H. Gannon, M.A. Zasloff, R. Taub, M. Muenke, F.S. Kaplan (1996) Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva. N Engl J Med 335: 555–561.
13.
Shen, Q., S.C. Little, M. Xu, J. Haupt, C. Ast, T. Katagiri, S. Mundlos, P. Seemann, F.S. Kaplan, M.C. Mullins, E.M. Shore (2009) The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. J Clin Invest 119: 3462–3472.
14.
Shore, E.M., M. Xu, G.J. Feldman, D.A. Fenstermacher, M.A. Brown, F.S. Kaplan (2006) A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 38: 525–527.
15.
Song, G.A., H.J. Kim, K.M. Woo, J.H. Baek, G.S. Kim, J.Y. Choi, H.M. Ryoo (2010) Molecular consequences of the ACVR1 (R206H) mutation of fibrodysplasia ossificans progressiva. J Biol Chem 285: 22542–22553.
16.
van Dinther, M., N. Visser, D.J. de Gorter, J. Doorn, M.J. Goumans, J. de Boer, P. ten Dijke (2010) ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. J Bone Miner Res 25: 1208–1215.
17.
Wang, T., P.K. Donahoe (2004) The immunophilin FKBP12: a molecular guardian of the TGF-β family type I receptors. Front Biosci 9: 619–631.
18.
Weiser, R., J.L. Wrana, J. Massagué (1995) GS domain mutations that constitutively activate TβR-I, the downstream signaling component in the TGF-β receptor complex. EMBO J 14: 2199–2208.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.